Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Modeling the Embrace of a Mutator: APOBEC Selection of Nucleic Acid Ligands.

Salter JD, Smith HC.

Trends Biochem Sci. 2018 May 23. pii: S0968-0004(18)30096-3. doi: 10.1016/j.tibs.2018.04.013. [Epub ahead of print] Review.

2.

A New Class of Antiretroviral Enabling Innate Immunity by Protecting APOBEC3 from HIV Vif-Dependent Degradation.

Bennett RP, Salter JD, Smith HC.

Trends Mol Med. 2018 May;24(5):507-520. doi: 10.1016/j.molmed.2018.03.004. Epub 2018 Mar 30. Review.

PMID:
29609878
3.

Transient Relative Age Effects across annual age groups in National level Australian Swimming.

Cobley S, Abbott S, Dogramaci S, Kable A, Salter J, Hintermann M, Romann M.

J Sci Med Sport. 2018 Aug;21(8):839-845. doi: 10.1016/j.jsams.2017.12.008. Epub 2017 Dec 29.

PMID:
29398369
4.

Progesterone transfer among cohabitating female big brown bats (Eptesicus fuscus).

Greville LJ, Pollock T, Salter JC, Faure PA, deCatanzaro D.

Gen Comp Endocrinol. 2017 Jun 1;247:199-204. doi: 10.1016/j.ygcen.2017.02.003. Epub 2017 Feb 7.

PMID:
28185935
5.

A comparison of statistical emulation methodologies for multi-wave calibration of environmental models.

Salter JM, Williamson D.

Environmetrics. 2016 Dec;27(8):507-523. doi: 10.1002/env.2405. Epub 2016 Sep 12.

6.

An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.

Bennett RP, Stewart RA, Hogan PA, Ptak RG, Mankowski MK, Hartman TL, Buckheit RW Jr, Snyder BA, Salter JD, Morales GA, Smith HC.

Antiviral Res. 2016 Dec;136:51-59. doi: 10.1016/j.antiviral.2016.11.001. Epub 2016 Nov 5.

7.

The APOBEC Protein Family: United by Structure, Divergent in Function.

Salter JD, Bennett RP, Smith HC.

Trends Biochem Sci. 2016 Jul;41(7):578-594. doi: 10.1016/j.tibs.2016.05.001. Epub 2016 Jun 6. Review.

8.

Structural and functional assessment of APOBEC3G macromolecular complexes.

Polevoda B, McDougall WM, Bennett RP, Salter JD, Smith HC.

Methods. 2016 Sep 1;107:10-22. doi: 10.1016/j.ymeth.2016.03.006. Epub 2016 Mar 14.

9.

RNA binding to APOBEC3G induces the disassembly of functional deaminase complexes by displacing single-stranded DNA substrates.

Polevoda B, McDougall WM, Tun BN, Cheung M, Salter JD, Friedman AE, Smith HC.

Nucleic Acids Res. 2015 Oct 30;43(19):9434-45. doi: 10.1093/nar/gkv970. Epub 2015 Sep 30.

10.

Low Sugar Is Not Always Good: Impact of Specific O-Glycan Defects on Tip Growth in Arabidopsis.

Velasquez SM, Marzol E, Borassi C, Pol-Fachin L, Ricardi MM, Mangano S, Juarez SP, Salter JD, Dorosz JG, Marcus SE, Knox JP, Dinneny JR, Iusem ND, Verli H, Estevez JM.

Plant Physiol. 2015 Jul;168(3):808-13. doi: 10.1104/pp.114.255521. Epub 2015 May 5. No abstract available.

11.

Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.

Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC.

Exp Dermatol. 2015 Jul;24(7):529-35. doi: 10.1111/exd.12710. Epub 2015 May 8.

12.

Anaphylaxis-related deaths in Ontario: a retrospective review of cases from 1986 to 2011.

Xu YS, Kastner M, Harada L, Xu A, Salter J, Waserman S.

Allergy Asthma Clin Immunol. 2014 Jul 22;10(1):38. doi: 10.1186/1710-1492-10-38. eCollection 2014.

13.

Structural insights for HIV-1 therapeutic strategies targeting Vif.

Salter JD, Morales GA, Smith HC.

Trends Biochem Sci. 2014 Sep;39(9):373-80. doi: 10.1016/j.tibs.2014.07.001. Epub 2014 Aug 12. Review.

14.

The effect of convective heating on evaporative heat loss in anesthetized children.

Cassey J, Salter J, Colyvas K, Burstal R, Stanger R.

Paediatr Anaesth. 2014 Dec;24(12):1274-80. doi: 10.1111/pan.12454. Epub 2014 Jun 26.

PMID:
24964827
15.

The multifaceted roles of RNA binding in APOBEC cytidine deaminase functions.

Prohaska KM, Bennett RP, Salter JD, Smith HC.

Wiley Interdiscip Rev RNA. 2014 Jul-Aug;5(4):493-508. doi: 10.1002/wrna.1226. Epub 2014 Mar 24. Review.

16.

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.

Arnedos M, Drury S, Afentakis M, A'Hern R, Hills M, Salter J, Smith IE, Reis-Filho JS, Dowsett M.

Ann Oncol. 2014 Mar;25(3):605-10. doi: 10.1093/annonc/mdt575. Epub 2014 Feb 12.

17.

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab.

Zabaglo L, Stoss O, Rüschoff J, Zielinski D, Salter J, Arfi M, Bradbury I, Dafni U, Piccart-Gebhart M, Procter M, Dowsett M; HERA Trial Study Team.

Ann Oncol. 2013 Nov;24(11):2761-6. doi: 10.1093/annonc/mdt275. Epub 2013 Jul 25.

PMID:
23894039
18.

Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.

Afentakis M, Dowsett M, Sestak I, Salter J, Howell T, Buzdar A, Forbes J, Cuzick J.

Breast Cancer Res Treat. 2013 Jul;140(2):253-62. doi: 10.1007/s10549-013-2628-5. Epub 2013 Jul 13.

PMID:
23852223
19.

Comment on Effect of drying of jujubes (Ziziphus jujuba Mill.) on the contents of sugars, organic acids, α-tocopherol, β-carotene, and phenolic compounds.

Salter JS Jr, Kang J.

J Agric Food Chem. 2013 May 15;61(19):4663-4. doi: 10.1021/jf305121u. Epub 2013 May 2. No abstract available.

PMID:
23638735
20.

Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.

Dunbier AK, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P, A'hern R, Miller WR, Smith IE, Dowsett M.

Clin Cancer Res. 2013 May 15;19(10):2775-86. doi: 10.1158/1078-0432.CCR-12-1000. Epub 2013 Mar 14.

21.

Core-binding factor β increases the affinity between human Cullin 5 and HIV-1 Vif within an E3 ligase complex.

Salter JD, Lippa GM, Belashov IA, Wedekind JE.

Biochemistry. 2012 Nov 6;51(44):8702-4. doi: 10.1021/bi301244z. Epub 2012 Oct 25.

22.

Positive and negative affect in individuals with spinal cord injuries.

Salter JE, Smith SD, Ethans KD.

Spinal Cord. 2013 Mar;51(3):252-6. doi: 10.1038/sc.2012.105. Epub 2012 Sep 11.

PMID:
22964753
23.

Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer.

Weigel MT, Banerjee S, Arnedos M, Salter J, A'Hern R, Dowsett M, Martin LA.

Ann Oncol. 2013 Jan;24(1):126-33. doi: 10.1093/annonc/mds240. Epub 2012 Aug 2.

PMID:
22865780
24.

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.

Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL.

Nat Med. 2012 Jul;18(7):1052-9. doi: 10.1038/nm.2795.

25.

Recent Advances on the Posttranslational Modifications of EXTs and Their Roles in Plant Cell Walls.

Velasquez M, Salter JS, Dorosz JG, Petersen BL, Estevez JM.

Front Plant Sci. 2012 May 15;3:93. doi: 10.3389/fpls.2012.00093. eCollection 2012.

26.

Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.

Lundgren K, Brown M, Pineda S, Cuzick J, Salter J, Zabaglo L, Howell A, Dowsett M, Landberg G; TransATAC investigators.

Breast Cancer Res. 2012 Apr 4;14(2):R57.

27.

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.

Pinhel I, Hills M, Drury S, Salter J, Sumo G, A'Hern R, Bliss JM, Sestak I, Cuzick J, Barrett-Lee P, Harris A, Dowsett M; NCRI Adjuvant Breast Cancer Trial Management Group.

Breast Cancer Res. 2012 Mar 14;14(2):R46.

28.

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M; ATAC trialists.

J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6. Erratum in: J Natl Cancer Inst. 2012 Nov 21;104(22):1772.

29.

Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.

Dowsett M, Smith I, Robertson J, Robison L, Pinhel I, Johnson L, Salter J, Dunbier A, Anderson H, Ghazoui Z, Skene T, Evans A, A'Hern R, Iskender A, Wilcox M, Bliss J.

J Natl Cancer Inst Monogr. 2011;2011(43):120-3. doi: 10.1093/jncimonographs/lgr034.

PMID:
22043057
30.

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF.

J Clin Oncol. 2011 Nov 10;29(32):4273-8. doi: 10.1200/JCO.2010.31.2835. Epub 2011 Oct 11.

PMID:
21990413
31.

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF; International Ki-67 in Breast Cancer Working Group.

J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64. doi: 10.1093/jnci/djr393. Epub 2011 Sep 29.

32.

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.

Drury SC, Detre S, Leary A, Salter J, Reis-Filho J, Barbashina V, Marchio C, Lopez-Knowles E, Ghazoui Z, Habben K, Arbogast S, Johnston S, Dowsett M.

Endocr Relat Cancer. 2011 Aug 30;18(5):565-77. doi: 10.1530/ERC-10-0046. Print 2011 Oct.

33.

Predictive algorithms for adjuvant therapy: TransATAC.

Dowsett M, Salter J, Zabaglo L, Mallon E, Howell A, Buzdar AU, Forbes J, Pineda S, Cuzick J.

Steroids. 2011 Jul;76(8):777-80. doi: 10.1016/j.steroids.2011.02.032. Epub 2011 Apr 4.

PMID:
21470560
34.

Association between breast cancer subtypes and response to neoadjuvant anastrozole.

Dunbier AK, Anderson H, Ghazoui Z, Salter J, Parker JS, Perou CM, Smith IE, Dowsett M.

Steroids. 2011 Jul;76(8):736-40. doi: 10.1016/j.steroids.2011.02.025. Epub 2011 Apr 5.

PMID:
21447351
35.

Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.

Ghazoui Z, Buffa FM, Dunbier AK, Anderson H, Dexter T, Detre S, Salter J, Smith IE, Harris AL, Dowsett M.

Clin Cancer Res. 2011 May 1;17(9):3005-12. doi: 10.1158/1078-0432.CCR-10-1704. Epub 2011 Feb 15. Erratum in: Clin Cancer Res. 2011 Jul 15;17(14):4915. Clin Cancer Res. 2011 May 1;17(9). doi:10.1158/1078-0432.CCR-11-1325.

36.

Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer.

Jones RL, Rojo F, A'Hern R, Villena N, Salter J, Corominas JM, Servitja S, Smith IE, Rovira A, Reis-Filho JS, Dowsett M, Albanell J.

J Clin Pathol. 2011 Feb;64(2):130-5. doi: 10.1136/jcp.2010.082966. Epub 2010 Dec 8.

PMID:
21148141
37.

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.

Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A'hern R, Nerurkar A, Osin P, Smith IE, Dowsett M.

Breast Cancer Res. 2010;12(5):R76. doi: 10.1186/bcr2719. Epub 2010 Sep 28.

38.

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.

Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, Orr N, Parton M, Smith IE, Reis-Filho JS, Dowsett M, Ashworth A, Turner NC.

Clin Cancer Res. 2010 Dec 15;16(24):6159-68. doi: 10.1158/1078-0432.CCR-10-1027. Epub 2010 Aug 27.

39.

Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.

Martin LA, Davies GL, Weigel MT, Betambeau N, Hills MJ, Salter J, Walsh G, A'Hern R, Dowsett M.

Breast Cancer Res Treat. 2010 Oct;123(3):829-36. doi: 10.1007/s10549-010-1100-z. Epub 2010 Aug 10.

PMID:
20697803
40.

Comparative validation of the SP6 antibody to Ki67 in breast cancer.

Zabaglo L, Salter J, Anderson H, Quinn E, Hills M, Detre S, A'Hern R, Dowsett M.

J Clin Pathol. 2010 Sep;63(9):800-4. doi: 10.1136/jcp.2010.077578. Epub 2010 Jul 29.

PMID:
20671052
41.

High-efficiency genotype analysis from formalin-fixed, paraffin-embedded tumor tissues.

Sikora MJ, Thibert JN, Salter J, Dowsett M, Johnson MD, Rae JM.

Pharmacogenomics J. 2011 Oct;11(5):348-58. doi: 10.1038/tpj.2010.50. Epub 2010 Jun 15.

42.

Feasibility of using tissue microarray cores of paraffin-embedded breast cancer tissue for measurement of gene expression: a proof-of-concept study.

Drury S, Salter J, Baehner FL, Shak S, Dowsett M.

J Clin Pathol. 2010 Jun;63(6):513-7. doi: 10.1136/jcp.2010.075754.

PMID:
20498025
43.

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.

Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, Baehner FL, Shak S.

J Clin Oncol. 2010 Apr 10;28(11):1829-34. doi: 10.1200/JCO.2009.24.4798. Epub 2010 Mar 8.

PMID:
20212256
44.

Relationship between Mediterranean Diet Score and atherothrombotic risk: findings from the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994.

Carter SJ, Roberts MB, Salter J, Eaton CB.

Atherosclerosis. 2010 Jun;210(2):630-6. doi: 10.1016/j.atherosclerosis.2009.12.035. Epub 2010 Jan 14.

PMID:
20138282
45.

Who would have thought a single Ki67 measurement would predict long-term outcome?

Dowsett M, A'Hern R, Salter J, Zabaglo L, Smith IE.

Breast Cancer Res. 2009;11 Suppl 3:S15. doi: 10.1186/bcr2434. Epub 2009 Dec 18. No abstract available.

46.

A hydrodynamic analysis of APOBEC3G reveals a monomer-dimer-tetramer self-association that has implications for anti-HIV function.

Salter JD, Krucinska J, Raina J, Smith HC, Wedekind JE.

Biochemistry. 2009 Nov 17;48(45):10685-7. doi: 10.1021/bi901642c.

47.

Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.

Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M.

Breast Cancer Res Treat. 2010 Jan;119(2):315-23. doi: 10.1007/s10549-009-0329-x. Epub 2009 Feb 27.

PMID:
19247830
48.

APOBEC3G subunits self-associate via the C-terminal deaminase domain.

Bennett RP, Salter JD, Liu X, Wedekind JE, Smith HC.

J Biol Chem. 2008 Nov 28;283(48):33329-36. doi: 10.1074/jbc.M803726200. Epub 2008 Oct 8.

49.

Variability in bleeding phenotype in Amish carriers of haemophilia B with the 31008 C-->T mutation.

Sharathkumar A, Hardesty B, Greist A, Salter J, Kerlin B, Heiman M, Sulkin M, Shapiro A.

Haemophilia. 2009 Jan;15(1):91-100. doi: 10.1111/j.1365-2516.2008.01792.x. Epub 2008 Jul 24.

PMID:
18721150
50.

Structural effects of nucleobase variations at key active site residue Ade38 in the hairpin ribozyme.

MacElrevey C, Salter JD, Krucinska J, Wedekind JE.

RNA. 2008 Aug;14(8):1600-16. doi: 10.1261/rna.1055308. Epub 2008 Jul 2.

Supplemental Content

Loading ...
Support Center